Acceptability & Safety of Two Sequential Doses of Psilocybin in Bipolar Disorder II Depression and Suicidality
The purpose of the study is to assess the safety and acceptability of up to two sequential administrations of 25 mg psilocybin with additional therapeutic support in decreasing suicidality in patients with Bipolar Disorder (BD II) depression.
- Status
- recruiting
- Phase
- Phase 2
- Institution
- The University of Texas Health Science Center, Houston
- Principal investigator
- Thomas Meyer, PhD
- Start date
- 2025-07-07
- End date
- 2027-01-01
- Registry ID
- NCT06706232
Tracked by the DMT Code Clinical Trials Observatory, an open record of DMT-related clinical research.